Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × tocilizumab × Clear all

Phase

Phase 1 2 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 3 Carcinoma, Non-Small-Cell Lung 3 Ovarian Neoplasms 2 Multiple Myeloma 2 Lymphoma, B-Cell 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma 1 Nasopharyngeal Neoplasms 1 Mesothelioma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Liver Neoplasms 1 Kidney Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Burkitt Lymphoma 1 Advanced Liver Cancers 1

Interventions

Dexamethasone 24 Cyclophosphamide 21 venetoclax 17 fludarabine 12 Lenalidomide 12 Bortezomib 12 pembrolizumab 11 Cytarabine 11 Carboplatin 10 Calcium Dobesilate 10 Rituximab 8 pomalidomide 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 fludarabine phosphate 6 carfilzomib 6 selinexor 5 daratumumab 5 blinatumomab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 Bendamustine Hydrochloride 5 obinutuzumab 4 ibrutinib 4 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05533775 2026-03-06

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡